ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Bangkok Genomics Innovation PCL's annualized return on capital (ROC %) for the quarter that ended in Dec. 2025 was 35.50%.
As of today (2026-06-29), Bangkok Genomics Innovation PCL's WACC % is 10.30%. Bangkok Genomics Innovation PCL's ROC % is 20.18% (calculated using TTM income statement data).
Bangkok Genomics Innovation PCL generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Bangkok Genomics Innovation PCL's WACC % is 10.30%. Bangkok Genomics Innovation PCL's ROC % is 20.18% (calculated using TTM income statement data).
Bangkok Genomics Innovation PCL generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
Be Aware
Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Bangkok Genomics Innovation PCL ROC % Related Terms
Bangkok Genomics Innovation PCL ROC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Operating Income data used here is four times the quarterly (Dec. 2025) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bangkok Genomics Innovation PCL (BKK:BKGI) has a ROC % of 35.50% as of Dec. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Bangkok Genomics Innovation PCL and its competitors.
Is Bangkok Genomics Innovation PCL's ROC % too high?
Bangkok Genomics Innovation PCL's current ROC % is 35.50%. Overall, Bangkok Genomics Innovation PCL has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Bangkok Genomics Innovation PCL's ROC % compare to TMO and DHR?
Bangkok Genomics Innovation PCL's ROC % of 35.50% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Medical Diagnostics & Research company?
A good ROC % depends on the Medical Diagnostics & Research industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Bangkok Genomics Innovation PCL and its competitors. Bangkok Genomics Innovation PCL's current ROC % is 35.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Genomics Innovation PCL stock overvalued right now?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a current ROC % of 35.50%. The current ROC % is 35.50%. Bangkok Genomics Innovation PCL's overall GF Score™ is 45/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Bangkok Genomics Innovation PCL (BKK:BKGI), the current ROC % is 35.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bangkok Genomics Innovation PCL Business Description
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Sale of laboratory reagents and related products; Testing and analysis services, which derives maximum revenue; and Sale and advanced therapy medicinal product.
45GF Score
Get the complete analysis for BKK:BKGI
ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BKGI has been successfully added to your 
